Evaluating the Efficacy and Safety of the Lower Dose of Bortezomib Plus Busulfan and Melphalan as a Conditioning Regimen in Patients With Multiple Myeloma Undergoing Autologous Peripheral Blood Stem Cell Transplantation- KMM103 Study

Press/Media: Press / Media

Period2018 Oct 2

Media coverage

1

Media coverage

  • TitleEvaluating the Efficacy and Safety of the Lower Dose of Bortezomib Plus Busulfan and Melphalan as a Conditioning Regimen in Patients With Multiple Myeloma Undergoing Autologous Peripheral Blood Stem Cell Transplantation- KMM103 Study
    Media name/outletClinical Trials.gov
    Country/TerritoryUnited States
    Date18/10/2
    PersonsHyun-Sook Kim, Hyun Mee Kim, Jinseok Kim
View all 1
View less